Skip to main content
. Author manuscript; available in PMC: 2016 May 1.
Published in final edited form as: Exp Neurol. 2014 Dec 2;267:18–29. doi: 10.1016/j.expneurol.2014.11.011

Fig. 1.

Fig. 1

Phrenic motor neuron survival in CTB–SAP treated rats. A–F. Photomicrographs (4× A and D; 20× B, C, E, and F) depicting representative CTB stained sections from the C3–5 spinal ventral horn from a control rat (A–C), and a 25 μg CTB–SAP treated rat at 7 days (D–F). Framed regions in A and D are shown at higher magnification (20×) in B, C, E, and F. Notice the number and shape of healthy, pyramidal-shaped CTB(+) labeled phrenic motor neurons in the control rat (A–C) versus the paucity of surviving phrenic motor neurons after CTB–SAP treatment (D–F). G. CTB–SAP dose response of phrenic motor neuron survival. Phrenic motor neuron survival in control rats (CTB + SAP; white bar) and rats injected with either 25 (light gray bars) or 50 μg (dark gray bars) CTB–SAP at 3, 7, 14 or 28 days post-injection. Phrenic motor neuron survival is significantly decreased in all CTB–SAP treated versus control rats (*; p < 0.05). Rats at 3 days post-25 μg CTB–SAP had significantly greater phrenic motor neuron survival versus all other CTB–SAP treated rats (#; p < 0.05). Rats at 7 days post-25 μg CTB–SAP had greater phrenic motor neuron survival versus rats 14 days post-50 μg CTB–SAP ($; p < 0.05). Means ± 1 SEM. Scale bar at 4× = 400 μm, 20×= 50 μm.